Stanford Medicine researchers reported a molecular-glue style strategy that converts a cancer driver into a built-in kill switch, eradicating aggressive human lymphoma tumors in mice. The two-headed experimental compound, TCIP3, targets a mechanism distinct from standard inhibition by forcing the growth-driving protein into a context that leads to tumor cell breakdown. In another oncology mechanism, researchers described how astrocyte mitochondrial shuttles awaken dormant glioblastoma cells and help them evade immunity. The work, reported in Nature Communications, frames quiescent tumor cell survival as tied to metabolic signaling rather than only cell-cycle entry. Together, the studies emphasize a shift toward therapies that rewire tumor states—either by locking oncogenic drivers into lethal programs or by interrupting the metabolic circuits that keep tumors hidden.